DYNACIRC
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYNACIRC is an oral small-molecule capsule approved by GSK in 1990 for an undisclosed indication(s). The specific mechanism of action and therapeutic class are unknown based on available data.
LOE Approaching
Product approaching loss of exclusivity signals declining team resources and focus on transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero current job openings linked to DYNACIRC indicate minimal hiring and team stability at mature/declining stage. Working on this product offers limited career acceleration but provides stability and foundational commercial experience.
Brand ManagerField Sales Representative
Worked on DYNACIRC at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.